Q3 2026
EPS
$0.94
est $2.52-62.7%
Revenue
$2.06B
est $2.01B+2.9%
Direct costs surged to 76.8% of revenue from 71.4% a year ago, crushing net income 60% and triggering a brutal 63% EPS miss despite beating on sales and reaffirming full-year guidance.
![ICLR logo]()
ICON :
ICLR
ICLR
Stock Data
$164.51
$3.34 (2.07%)
Asset Type
Common Stock
Exchange
NASDAQ
Currency
USD
Country
USA
Sector
HEALTHCARE
Industry
DIAGNOSTICS & RESEARCH
Icon Plc is a global clinical research organization based in Dublin, Ireland, offering a wide range of services to the pharmaceutical, biotechnology, and medical device industries. The company specializes in managing all stages of the clinical development process, from early compound selection through to Phase I-IV clinical studies. Icon Plc provides comprehensive services including clinical trial management, consulting, laboratory services, and post-market commercialization support. With a focus on innovation, Icon Plc supports its clients in bringing new medicines and treatments to market efficiently and effectively.
Latest Activity
Q3 2026
EPS
$2.56
est $2.52+1.7%
Revenue
$2.06B
est $2.01B+2.9%
Clinical research outsourcer cleared both lines with a $3.12 billion in net bookings and a robust 1.51x book-to-bill ratio signaling solid pipeline demand, though margin pressure persists as the company reaffirmed full-year guidance.
Q2 2026
Company Update
ICON is navigating a restatement blowup tied to an SEC investigation that slashed $92.69 million from FY2024 revenue and wiped tens of millions from prior earnings, yet a $14.9 billion backlog with 48% expected to convert within 12 months offers a near-term lifeline.
Q2 2026
EPS
$2.50
est $2.55-1.9%
Revenue
$2.03B
est $1.99B+2.0%
ICON beat on revenue with $2.03 billion but missed earnings as unfavorable business mix and surging integration costs pressured margins, though strong bookings of $2.88 billion and a 1.42 book-to-bill ratio signal enduring commercial strength.
ICON plc reports earnings after the bell today, a key bellwether for clinical trial demand and biotech funding health.
All ICON Articles
3 Articles
